Condition: Squamous Non-small-cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Cervical Squamous Cell Carcinoma · Sponsor: Alentis Therapeutics AG
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.
This description comes directly from the study's public registry record.
Alentis Clinical Trial Contact · +41782304288 · patientinfo@alentis.ch
Always discuss trial participation with your own doctor first.
| Mayo Foundation for Medical Education and Research - Mayo Cl | Scottsdale, Arizona, United States | Recruiting |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Yale Comprehensive Cancer Center | New Haven, Connecticut, United States | Recruiting |
| The University of Chicago Medical Center - Oncology | Chicago, Illinois, United States | Recruiting |
| Norton Cancer Institue Downtown | Louisville, Kentucky, United States | Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| NEXT Oncology Virginia | Fairfax, Virginia, United States | Recruiting |
| Institut Bergonie | Bordeaux, France | Recruiting |
| Centre Georges Francois Leclerc - Oncologie Medicale | Dijon, France | Recruiting |
| CHRU De Lille- Hôpital Claude Huriez - Medical Oncology | Lille, France | Recruiting |
| AP-HM Hôpital de La Timone CEPCM | Marseille, France | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06747585